|
In Vitro Anti-Herpes Simplex Virus Activities of PienTze Huang |
|---|---|
| รหัสดีโอไอ | |
| Creator | Kasidit Charnnirutti |
| Title | In Vitro Anti-Herpes Simplex Virus Activities of PienTze Huang |
| Contributor | 1)Monnaphruet Chanhom 2)Mali Wirotesangthong |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2562 |
| Journal Title | Isan Journal ofPharmaceutical Sciences |
| Journal Vol. | 15 |
| Journal No. | 1 |
| Page no. | 195-203 |
| Keyword | Pien Tze Huang, anti-HSV activity, modified plaque reduction assay, IC50, CC5 |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences; IJPS |
| ISSN | 19050852 |
| Abstract | Introduction:PienTze Huang (PZH), is a popular traditional Chinese medicine formula used for treat liver diseases, cancers and inflammation. Little is known about any antiviral activity of PZH. PZH with anti-herpes simplex virus (HSV) activity has not been reported yet.The aim of this study was to investigate effects of PZH on HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infectionsin vitro. Method: Modified plaque reduction assay was used to demonstrate the effectsof PZH on HSV-1, KOS strain and HSV-2, Baylor 186 strain, compared with those of acyclovir (ACV).Results:The 50 % inhibition concentrations (ICs50) of PZH were 297.31 ? 16.72 and 283.99 ? 28.93 ?g/ml for HSV-1 and HSV-2, respectively. Whereas the IC50 of ACV were 0.21 ? 0.012 and 0.63 ? 0.18 ?g/ml for HSV-1 and HSV-2, subsequently. Cytotoxicity test showed that the 50 % cytotoxic concentrations (CCs50) of PZH and ACV were 1,414.21 and 282.24 ?g/ml, respectively. Moreover, thetherapeutic indexs (TIs) of PZH were 4.75 and4.98; and those of ACV were 1,340.48 and 451.82 for HSV-1 and HSV-2, subsequently. Conclusion: The results of this study were first revealed that PZH possess anti-HSV activitiesbut the TIs were slightly low. Consequently, PZH possesses anti-HSV activities but is not suitable for treatment patient with single HSV infection. PZH might be used for treatment patient with cancer and HSV infection. However, the further studies, in vivo and clinical trials are necessary for supporting our proposed treatment. |
